|

Valacyclovir Clinical Trials

3 actively recruiting trials across 3 locations

▲ +1 trial since June 2026

Also known as: ValACV, Valaciclovir, Zelitrex

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1

Top Sponsors

  • University of Michigan Rogel Cancer Center1
  • M.D. Anderson Cancer Center1
  • Candel Therapeutics, Inc.1

Indications

  • Cancer3
  • Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant1
  • Recurrent Malignant Brain Neoplasm1
  • Resectable Brain Neoplasm1
  • Non-Squamous Non-Small Cell Lung Cancer1

Ann Arbor, Michigan1 trial

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

University of Michigan Comprehensive Cancer Center

Phase 1

New York, New York1 trial

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

Phase 3

Houston, Texas1 trial

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.